CN114040758A - 使用6,8-双-苄硫基-辛酸治疗淋巴瘤的治疗方法和组合物 - Google Patents

使用6,8-双-苄硫基-辛酸治疗淋巴瘤的治疗方法和组合物 Download PDF

Info

Publication number
CN114040758A
CN114040758A CN202080022886.3A CN202080022886A CN114040758A CN 114040758 A CN114040758 A CN 114040758A CN 202080022886 A CN202080022886 A CN 202080022886A CN 114040758 A CN114040758 A CN 114040758A
Authority
CN
China
Prior art keywords
lymphoma
bis
administered
benzylthio
octanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080022886.3A
Other languages
English (en)
Chinese (zh)
Inventor
T·S·帕尔德
J·埃德尔森
A·诺依
Z·拉玛尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wake Forrest University Health Sciences
Raphael Pharmaceutical Co ltd
Memorial Sloan Kettering Cancer Center
Original Assignee
Wake Forrest University Health Sciences
Raphael Pharmaceutical Co ltd
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wake Forrest University Health Sciences, Raphael Pharmaceutical Co ltd, Memorial Sloan Kettering Cancer Center filed Critical Wake Forrest University Health Sciences
Publication of CN114040758A publication Critical patent/CN114040758A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080022886.3A 2019-03-19 2020-03-19 使用6,8-双-苄硫基-辛酸治疗淋巴瘤的治疗方法和组合物 Pending CN114040758A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962820767P 2019-03-19 2019-03-19
US62/820,767 2019-03-19
PCT/US2020/023537 WO2020191144A1 (en) 2019-03-19 2020-03-19 Therapeutic methods and compositions for treating lymphoma using 6,8-bis-benzylthio-octanoic acid

Publications (1)

Publication Number Publication Date
CN114040758A true CN114040758A (zh) 2022-02-11

Family

ID=72519349

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080022886.3A Pending CN114040758A (zh) 2019-03-19 2020-03-19 使用6,8-双-苄硫基-辛酸治疗淋巴瘤的治疗方法和组合物

Country Status (11)

Country Link
US (1) US20220151994A1 (https=)
EP (1) EP3941453A4 (https=)
JP (1) JP2022525779A (https=)
KR (1) KR20220018959A (https=)
CN (1) CN114040758A (https=)
AU (1) AU2020240091A1 (https=)
BR (1) BR112021018138A2 (https=)
CA (1) CA3133101A1 (https=)
MX (1) MX2021011250A (https=)
TW (1) TW202102211A (https=)
WO (1) WO2020191144A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121645A1 (en) * 2018-12-20 2020-06-25 Rafael Pharmaceuticals, Inc. Oral therapy using 6,8-bis-benzylthio-octanoic acid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263653B2 (en) * 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives

Also Published As

Publication number Publication date
KR20220018959A (ko) 2022-02-15
WO2020191144A1 (en) 2020-09-24
AU2020240091A1 (en) 2021-09-30
EP3941453A4 (en) 2022-12-28
CA3133101A1 (en) 2020-09-24
JP2022525779A (ja) 2022-05-19
BR112021018138A2 (pt) 2021-11-16
TW202102211A (zh) 2021-01-16
MX2021011250A (es) 2022-02-11
US20220151994A1 (en) 2022-05-19
EP3941453A1 (en) 2022-01-26

Similar Documents

Publication Publication Date Title
US20250019388A1 (en) Stat3 degraders and uses thereof
CN105705148B (zh) 使用普那布林和紫杉烷的组合的癌症疗法
KR20190025733A (ko) 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법 및 약학적 조성물
KR20200096788A (ko) 화학치료법-내성 난소암 또는 유방암 치료에서 parp 억제제의 용도
WO2016168451A1 (en) Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
US20250275955A1 (en) Use of tivozanib to treat subjects with refractory cancer
KR20220011647A (ko) 소세포폐암의 병용 치료용 퀴놀린 유도체
US20250352535A1 (en) Mdm2 degraders and uses thereof
CN114040758A (zh) 使用6,8-双-苄硫基-辛酸治疗淋巴瘤的治疗方法和组合物
US20230132982A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
KR20220124739A (ko) 암의 치료를 위한 병용 요법
CN113509475A (zh) Bcl-2/bcl-xl抑制剂的组合及相关用途
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
AU2016259775A1 (en) Cabazitaxel and its use for treating cancer
US20230181544A1 (en) Dosing regimens for use in treating relapsed and refractory multiple myeloma with venetoclax
WO2025209479A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
CN1901906A (zh) 治疗套细胞淋巴瘤的cci－779
WO2024258916A1 (en) Stat3 degraders and uses thereof
JP2024531653A (ja) 固形腫瘍の処置のための経口投与パクリタキセル、Ｐ－ｇｐ阻害剤、およびチェックポイント阻害剤の治療的組み合わせ
WO2025250888A1 (en) Resiquimod in combination with a pd-1 or pd-l1 antagonist for treating cancer
WO2024222705A1 (zh) 用于治疗pd-l1表达阳性局部晚期或转移性nsclc患者的药物及其用途
KR20250055565A (ko) 티로신 키나아제 억제제 보도바티닙을 사용하여 만성 골수성 백혈병을 치료하는 방법
JP2022510258A (ja) デビミスタットを使用して急性骨髄性白血病を治療するための治療方法および組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination